Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

PCR Testing: XPhyto Disrupts a Blockbuster Business

It’s the technological evolution that could transform the US $84.4 billion Covid-19 diagnostics market. Vancouver-based life sciences company XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) expects its rapid Covid-19 test system to be approv...
Marc Davis | February 25, 2021 |

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. Immuno-pharmaceutical company AIM Imm...
Streetwise Reports | March 10, 2020 |

Gilead, Teva, XPhyto - Global marketing potential

The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border...
Mario Hose | June 16, 2020 |

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can b...
Mario Hose | July 15, 2020 |

XPhyto: Buyouts, Biosensors and a Booming Business

Test, test, test! It’s the World Health Organization’s battle cry in the global war against COVID-19 and other coronaviruses – including future outbreaks. And it is not getting any less resonant as new variants continue to cause ha...
Marc Davis | August 3, 2021 |

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

The Germans call it COVID-19 “rapid testing mania”. But like most manias, it has opened up a Pandora’s box of problems. As the speed of the vaccine rollout program falters in Europe, on-the-spot antigen testing continues to be the ...
Marc Davis | June 2, 2021 |

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of i...
Mario Hose | April 24, 2020 |

XPhyto: Why Rapid PCR Testing is Here to Stay

Regular coronavirus testing is destined to become the norm for many years to come, regardless of how many people get vaccinated against COVID-19. So says Hugh Rogers, the CEO of XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) ( OTC: XPHYF ) , a Canadian life scie...
Marc Davis | April 22, 2021 |
1 2 3 4 5 6 7 8 9 10 ...